Eloxx Pharmaceuticals (ELOX) Gets a Hold Rating from H.C. Wainwright
May 09 2022 - 06:30AM
TipRanks
H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on
Eloxx Pharmaceuticals (ELOX – Research Report) today and set a
price target of $0.50. The company's shares closed last Friday at
$0.33, close to its 52-week low of $0.29. According to
TipRanks.com, Fein is currently ranked with 0 stars on a 0-5 stars
ranking scale, with an average return of -19.6% and a 22.9% success
rate. Fein covers the Healthcare sector, focusing on stocks such as
DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and
Global Blood Therapeutics. Eloxx Pharmaceuticals has an analyst
consensus of Moderate Buy, with a price target consensus of
$2.50.
https://www.tipranks.com/news/blurbs/eloxx-pharmaceuticals-elox-gets-a-hold-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2023 to Apr 2023
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2022 to Apr 2023
